Incannex reports positive results from phase 2 clinical trial of psx-001 (psi-gad) for generalised anxiety disorder

Melbourne, australia and new york, aug. 26, 2025 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl) (“incannex” or the “company”) is pleased to report positive data from its phase 2 clinical trial of psx-001 (formerly psi-gad), a psilocybin-assisted psychotherapy treatment for generalised anxiety disorder (gad). the results confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study, reinforcing psx-001's potential as a best-in-class therapy for patients with moderate to severe gad.
PSX Ratings Summary
PSX Quant Ranking